Group 1 - The core viewpoint of the news is that Huaxia Eye Hospital has shown a slight decline in stock price and has experienced significant financing activities, indicating a mixed sentiment among investors [1] - As of December 31, Huaxia Eye Hospital's stock price fell by 0.06%, with a trading volume of 55.95 million yuan. The net financing buy was -4.74 million yuan, indicating more financing repayment than buying [1] - The total financing and securities balance for Huaxia Eye Hospital reached 192 million yuan, with the financing balance accounting for 1.26% of the circulating market value, which is above the 90th percentile of the past year [1] Group 2 - As of September 30, the number of shareholders for Huaxia Eye Hospital increased to 21,200, a rise of 0.58%, while the average circulating shares per person decreased by 0.57% to 15,489 shares [2] - For the period from January to September 2025, Huaxia Eye Hospital reported a revenue of 3.272 billion yuan, reflecting a year-on-year growth of 2.83%, and a net profit attributable to shareholders of 434 million yuan, up by 3.04% [2] - Since its A-share listing, Huaxia Eye Hospital has distributed a total of 507 million yuan in dividends [3]

Group 1 - The core point of the news is that Huaxia Eye Hospital's stock has experienced a decline of 1.04%, with a total market value of 15.128 billion yuan and a cumulative drop of 0.6% over the last three days [1] - Huaxia Eye Hospital Group, established on August 12, 2004, specializes in ophthalmology services, with revenue composition as follows: refractive projects 36.90%, comprehensive optometry projects 24.04%, cataract projects 20.14%, posterior segment projects 12.94%, and others 5.99% [1] - The stock's trading volume was 36.5619 million yuan, with a turnover rate of 0.31% [1] Group 2 - Huaxia Eye Hospital's major circulating shareholder is Huabao Fund, which reduced its holdings in the Huabao CSI Medical ETF (512170) by 1.1664 million shares, now holding 7.1388 million shares, representing 2.17% of circulating shares [2] - The estimated floating loss for Huabao CSI Medical ETF today is approximately 1.3564 million yuan, with a cumulative floating loss of 785,300 yuan during the three-day decline [2] - The Huabao CSI Medical ETF was established on May 20, 2019, with a current scale of 26.404 billion yuan and a year-to-date return of 5.42%, ranking 3760 out of 4195 in its category [2]

Core Viewpoint - Huaxia Eye Hospital announced the approval of several key resolutions during the 12th meeting of its third board of directors, including the election of the fourth board of directors and the termination of the 2025 employee stock ownership plan [1] Group 1 - The company approved the proposal for the election of non-independent director candidates for the fourth board of directors [1] - The company approved the proposal for the election of independent director candidates for the fourth board of directors [1] - The company decided to terminate the implementation of the 2025 employee stock ownership plan [1]

Group 1 - The company Huaxia Eye Hospital (301267) announced that it will hold its first extraordinary shareholders' meeting on January 14, 2026, at 14:30 [1] - The agenda includes the election of non-independent and independent directors by the board, utilizing a cumulative voting system [1] - The voting will be conducted both on-site and online [1]

Core Viewpoint - The company, Huaxia Eye Hospital (301267.SZ), has decided to terminate its employee stock ownership plan due to the impact of industry collective procurement policies and healthcare payment reform on its operations, which has led to a deviation from performance assessment indicators set for the plan [1] Group 1 - The company acknowledges that objective factors such as industry collective procurement policies and healthcare payment reform continue to affect its operations [1] - The company anticipates that the current business situation will not align with the performance assessment indicators of the employee stock ownership plan, making it difficult to achieve the intended motivational purpose and effect [1] - The decision to terminate the employee stock ownership plan was made after careful consideration of the long-term development of the company and the interests of employees, as well as the willingness of participating employees and the company's actual situation [1] Group 2 - The company’s board of directors has decided to terminate the implementation of the employee stock ownership plan ahead of schedule [1] - Along with the termination of the employee stock ownership plan, the company will also terminate related documents such as the "2025 Employee Stock Ownership Plan Management Measures" [1]

Group 1 - The core point of the article is that Huaxia Eye Hospital announced the termination of its 2025 employee stock ownership plan during its board meeting held on December 29, 2025 [1] - For the first half of 2025, Huaxia Eye Hospital's revenue composition is as follows: refractive services accounted for 36.9%, comprehensive optometry projects 24.04%, cataract services 20.14%, posterior segment projects 12.94%, and other businesses 5.99% [1] - As of the report date, Huaxia Eye Hospital has a market capitalization of 15.3 billion yuan [1]

华厦眼科医院集团股份有限公司 独立董事提名人声明与承诺 提名人华厦眼科医院集团股份有限公司董事会现就提名 王志强 为华 厦眼科医院集团股份有限公司第四届董事会独立董事候选人发表公开声明。被 提名人已书面同意作为华厦眼科医院集团股份有限公司第四届董事会独立董事 候选人（参见该独立董事候选人声明）。本次提名是在充分了解被提名人职 业、学历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录等情 况后作出的，本提名人认为被提名人符合相关法律、行政法规、部门规章、规 范性文件和深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要 求，具体声明并承诺如下事项： 一、被提名人已经通过华厦眼科医院集团股份有限公司第三届董事会提名 委员会资格审查，提名人与被提名人不存在利害关系或者其他可能影响独立履 职情形的密切关系。 ☑ 是 □ 否 如否，请详细说明： 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规 定不得担任公司董事的情形。 （王志强） ☑ 是 □ 否 如否，请详细说明： 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳 证券交易所业务规则规定的独立董事任职资格和条件。 ☑ 是 □ 否 ...

独立董事提名人声明与承诺 华厦眼科医院集团股份有限公司 （郑文礼） 提名人华厦眼科医院集团股份有限公司董事会现就提名 郑文礼 为华 厦眼科医院集团股份有限公司第四届董事会独立董事候选人发表公开声明。被 提名人已书面同意作为华厦眼科医院集团股份有限公司第四届董事会独立董事 候选人（参见该独立董事候选人声明）。本次提名是在充分了解被提名人职 业、学历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录等情 况后作出的，本提名人认为被提名人符合相关法律、行政法规、部门规章、规 范性文件和深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要 求，具体声明并承诺如下事项： 一、被提名人已经通过华厦眼科医院集团股份有限公司第三届董事会提名 委员会资格审查，提名人与被提名人不存在利害关系或者其他可能影响独立履 职情形的密切关系。 ☑ 是 □ 否 如否，请详细说明： 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规 定不得担任公司董事的情形。 ☑ 是 □ 否 如否，请详细说明： 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳 证券交易所业务规则规定的独立董事任职资格和条件。 ☑ 是 □ 否 ...

证券代码：301267 证券简称：华厦眼科 公告编号：2025-038 华厦眼科医院集团股份有限公司 关于董事会换届选举的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华厦眼科医院集团股份有限公司（以下简称"公司"）第三届董事会任期届 满，根据《公司法》《上市公司独立董事管理办法》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司 规范运作》等法律法规、规范性文件及《公司章程》等有关规定，公司按照相关 法律程序进行董事会换届选举。现将有关情况公告如下： 一、董事会换届选举情况 公司于 2025 年 12 月 29 日召开了第三届董事会第十二次会议，审议通过了 《关于公司董事会换届选举暨提名第四届董事会非独立董事候选人的议案》和 《关于公司董事会换届选举暨提名第四届董事会独立董事候选人的议案》。公司 第四届董事会将由 3 名非独立董事、3 名独立董事和 1 名职工代表董事组成。 经公司董事会提名委员会资格审查，公司董事会同意提名苏庆灿先生、陈凤 国先生、李晓峰先生为第四届董事会非独立董事候选人；提名傅元略 ...

声明人 郑文礼 作为华厦眼科医院集团股份有限公司第四届董事会独 立董事候选人，已充分了解并同意由提名人华厦眼科医院集团股份有限公司董 事会提名为华厦眼科医院集团股份有限公司（以下简称该公司）第四届董事会 独立董事候选人。现公开声明和保证，本人与该公司之间不存在任何影响本人 独立性的关系，且符合相关法律、行政法规、部门规章、规范性文件和深圳证 券交易所业务规则对独立董事候选人任职资格及独立性的要求，具体声明并承 诺如下事项： 一、本人已经通过华厦眼科医院集团股份有限公司第三届董事会提名委 员会资格审查，提名人与本人不存在利害关系或者其他可能影响独立履职 情形的密切关系。 ☑ 是 □ 否 如否，请详细说明： 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不 得担任公司董事的情形。 独立董事候选人声明与承诺 （郑文礼） 华厦眼科医院集团股份有限公司 ☑ 是 □ 否 ☑ 是 □ 否 如否，请详细说明： 五、本人已经参加培训并取得证券交易所认可的相关培训证明材料（如 有）。 如否，请详细说明： ☑ 是 □ 否 如否，请详细说明： ☑ 是 □ 否 如否，请详细说明： 四、本人符合该公司章程规定的独立董事任职条 ...